Zolpidem Tartrate

This page contains recent news articles, when available, and an overview of Zolpidem Tartrate but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Novacea, Inc. and Transcept Pharmaceuticals, Inc. Sign Merger ...  -  Sep 1, 2008
The lead Transcept product candidate is Intermezzo(R) (zolpidem tartrate sublingual lozenge), a uniquely delivered low dose formulation of zolpidem MarketWatch

TOP MARKET NEWS  -  Sep 1, 2008
...(RTTNews) - Intermezzo, or zolpidem tartrate sublingual lozenge, is Transcept's lead product candidate for sleep disorder Insomnia. RTT News,

FDA Safety Changes: Ambien, Primaxin IM/IV, Hepsera  -  Aug 28, 2008
Describe the risks associated with use of zolpidem tartrate for the treatment of insomnia. Describe the drug interaction between carbapenem antimicrobials Medscape (subscription)

School zone traffic stops put several persons in jail  -  Sep 11, 2008
There were three pills that included Zolpidem Tartrate, Promethazine Hydrochloride and an Acetaminopehn-hydrocodone. The three pills were labeled a Purcell Register,

Transcept Pharmaceuticals to Present at the BMO Capital Markets ...  -  Jul 23, 2008
The lead Transcept product candidate, Intermezzo(R) (zolpidem tartrate sublingual lozenge), is a low dose formulation of zolpidem for the treatment of PharmaLive.com (press release),

Transcept Pharmaceuticals to Present at the BMO Capital Markets ...  -  Jul 23, 2008
The lead Transcept product candidate, Intermezzo(R) (zolpidem tartrate sublingual lozenge), is a low dose formulation of zolpidem for the treatment of PR Newswire (press release),

수면 장애와 '멜ë?¼í† ë‹Œ(melatonin)'  -  Aug 6, 2008
...불면�과 관련해 처방�는 수면제들로는 졸피뎀 성분(zolpidem tartrate)� 졸피드(한미약품),졸피람(환�제약), 스틸녹스(사노피아벤티스) 등과 Triazolam(트리아졸 아�비타임즈,

Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets ...  -  Jun 10, 2008
..."The extended release formulation of zolpidem tartrate was found to be an effective adjunctive treatment option that helped patients fall asleep and stay Trading Markets (press release),

Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets ...  -  Jun 10, 2008
...'The extended release formulation of zolpidem tartrate was found tobe an effective adjunctive treatment option that helped patients fall asleepand stay istockAnalyst.com,

Transcept Pharmaceuticals Appoints Key Senior Executives  -  Jul 2, 2008
The lead Transcept product candidate, Intermezzo(R) (zolpidem tartrate lozenge), is a low dose formulation of zolpidem for the treatment of insomnia in Earthtimes (press release),

Intermezzo(R) 3.5 mg Achieves Greater Early Bioavailability Than ...  -  Jun 11, 2008
The lead Transcept product candidate, Intermezzo(R) (zolpidem tartrate sublingual lozenge), is a low dose formulation of zolpidem for the treatment of Earthtimes (press release),

Transcept Pharmaceuticals to Present at the Jefferies 2nd Annual ...  -  Jun 18, 2008
The lead Transcept product candidate, Intermezzo(R) (zolpidem tartrate sublingual lozenge), is a low dose formulation of zolpidem for the treatment of PR Newswire (press release),

Vanda Improves Sleep Onset in Phase III Insomnia Trial  -  Jun 26, 2008
The insomnia market is dominated by GABA modulators like Lunesta (eszopiclone, Sepracor Inc.) and Ambien CR (zolpidem tartrate extended-release, BioWorld Online,

Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets ...  -  Jun 10, 2008
..."The extended release formulation of zolpidem tartrate was found to be an effective adjunctive treatment option that helped patients fall asleep and stay SunHerald.com,

InvestSource Inc.: Global Entertainment Announces Major Deal to ...  -  Jun 11, 2008
June 10, 2008 -- Sanofi-aventis (NYSE: SNY | Quote | Chart | News | PowerRating) announced results from a new study that showed Ambien CR (zolpidem tartrate Trading Markets (press release),

Get a Deep Insight into the Sleep Disorders Market Analysis 2008-2018  -  May 12, 2008
A generic version of Ambien is expected to achieve strong market share by volume as there is a great demand for zolpidem tartrate for insomnia. Market Wire (press release)

Transcept Pharmaceuticals: Study of Intermezzo(R) by Leading Sleep ...  -  Apr 15, 2008
Intermezzo(R) (zolpidem tartrate sublingual lozenge) is a low dose formulation of zolpidem designed to treat insomnia in patients who awaken in the middle Earthtimes,

Sleep Disorders Market Analysis 2008-2018  -  Apr 11, 2008
A generic version of Ambien is expected to achieve strong market share by volume as there is a great demand for zolpidem tartrate for insomnia. PharmiWeb.com (press release),

Credit crunch sinks MonoSol IPO  -  Mar 30, 2008
These projects involve the sleeping aid Ambien (zolpidem tartrate, Sanofi Aventis), the anti-emetic Zofran (ondansetron hydrochloride, GlaxoSmithKline), In-PharmaTechnologist.com,

Generic drugs the prescription for saving money  -  Mar 28, 2008
The list includes 30 days of the sleep aid Ambien for $155.47, compared to $2.52 for the generic zolpidem tartrate. Valium costs $140 compared to $1.82 for The Saginaw News - MLive.com,

Transcept Pharmaceuticals to Present at the Susquehanna Financial ...  -  Feb 19, 2008
The lead Transcept product candidate, Intermezzo(R) (zolpidem tartrate lozenge), is a low dose sublingual formulation of zolpidem for the treatment of PharmaLive.com (press release),

Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO ...  -  07 Feb 2008
The lead Transcept product, Intermezzo(R) (zolpidem tartrate lozenge), is a low dose sublingual formulation of zolpidem for the treatment of insomnia in PR Newswire (press release),

NovaDel’s New Drug Application for ZolpiMistâ„¢ Oral Spray to Treat ...  -  Jan 23, 2008
Ambien®/Ambien CR™ (zolpidem tartrate) and generic zolpidem tartrate are the dominant prescription drugs totaling more than 70% of the market in 2006. Business Wire (press release),

Heath Ledger and the Ambien Panic  -  Jan 23, 2008
...connection to the prescription sleep aid Ambien (Zolpidem Tartrate), have left many confused and wary about the contents of their own medicine cabinets. Associated Content,

Desperate for sleep  -  Jan 29, 2008
Ambien (aka zolpidem tartrate in its generic form) has been grabbing headlines – the side effects connected with zolpidem would keep anyone awake. Toronto Star,

Campus Crime  -  Feb 4, 2008
...a bottle of Phenergan containing five pills and a green bottle of zolpidem tartrate prescribed to other individuals were found in Emerson's belongings. ASU Herald,

Grand jury indicts 102, including man who allegedly stabbed wife  -  Jan 23, 2008
...forgery, 9 counts; uttering, 9 counts; obtaining a controlled substance by fraud or subterfuge, to-wit: zolpidem tartrate (Ambien); conspiracy. Beckley Register-Herald (subscription),

Ambien: The Good, the Bad and Facts  -  Jan 23, 2008
According to RxList Ambien and Ambien Cr (zolpidem tartrate) is a non-benzodiazepine hypnotic of the imidazopyridine class. What that means is that the drug Associated Content,

Transcept Pharmaceuticals to Present at RBC Capital Markets 2007 ...  -  Dec 7, 2007
The lead Transcept product, Intermezzo(R) (zolpidem tartrate lozenge), is a low dose sublingual formulation of zolpidem that is currently in late phase 3 Reuters

Transcept Pharmaceuticals to Present at 19th Annual Piper Jaffray ...  -  Nov 14, 2007
The lead Transcept product, Intermezzo(R) (zolpidem tartrate lozenge), is a low dose sublingual formulation of zolpidem that is currently in late phase 3 PR Newswire (press release),

Transcept Pharmaceuticals to Present at 19th Annual Piper Jaffray ...  -  Nov 14, 2007
The lead Transcept product, Intermezzo(R) (zolpidem tartrate lozenge), is a low dose sublingual formulation of zolpidem that is currently in late phase 3 Earthtimes,

New Data Show Improvements in Work Performance in Patients with ...  -  Oct 24, 2007
...chronic insomnia who were treated with 12.5 mg of AMBIEN CR(R) (zolpidem tartrate extended- release) tablets CIV experienced significant improvements in CNNMoney.com

Transcept Pharmaceuticals to Present at the Acumen BioFin(TM ...  -  15 Oct 2007
The lead Transcept product, Intermezzo(TM) (zolpidem tartrate lozenge), is a low dose sublingual formulation of zolpidem that is currently in late phase 3 PharmaLive.com (press release),

Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum  -  Sep 28, 2007
Transcept's lead compound, Intermezzo(TM) (zolpidem tartrate lozenge), is a low dose formulation of zolpidem that is currently in late phase 3 clinical PR Newswire (press release),

Flamingo bags CRAMS order from Teva  -  Aug 8, 2007
..."Zolpidem tartrate tablets are used for the short-term treatment of insomnia and related disorders and have total annual market sales of $12 billion Express Pharma,

Flamingo enters into a pact with Teva  -  Jul 19, 2007
Economic Times,..."Zolpidem tartrate tablets are used for the short-term treatment of insomnia and related disorders and have total annual market sales of 12 billion

Sepracor Inc. Announces Second Quarter 2007 Results and ...  -  Jul 27, 2007
Genetic Engineering News (press release),This growth occurred despite introduction of the generic competitor, zolpidem tartrate, which occurred during the quarter. XOPENEX(R) brand levalbuterol HCl

Sepracor Q2 Profit Declines On Higher Costs, Expenses; Generic ...  -  Jul 27, 2007
RTT News,...$143 million from $139.1 million, despite introduction of the generic competitor, zolpidem tartrate, which occurred during the just concluded quarter.

Wockhardt launches insomnia drug Zolpidem in the US  -  Jun 8, 2007
Express Pharma,Zolpidem tartrate is one of the most widely used medicines to treat insomnia (sleep disorder) and is safer than most other sleeping pills in replicating

Oral sleep spray gets the nod  -  Jun 7, 2007
In-PharmaTechnologist.com,...announced results from two studies comparing its Zolpidem Oral Spray to Sanofi-Aventis' Ambien (zolpidem tartrate) tablets in the treatment of insomnia.

Growing Fierce  -  Jun 7, 2007
Drug Discovery & Development,On April 23, 2007, the US Food and Drug Administration (FDA) approved the first generic versions of Ambien, known as zolpidem tartrate, with 13 different

Zolpidem Tartrate Syrup (Zolpidem Tartrate capsule) Information  -  May 19, 2007
American Chronicle,Zolpidem Tartrate medication belong to Sedative and hypnotic class. Zolpidem Tartrate helps in the mechanism is unknown but may involve subunit modulation

Verispan's Vector One(R): Generic Ambien Becomes No. 1 Sleep ...  -  May 22, 2007
Genetic Engineering News (press release),Verispan's Vector One(R): National (VONA) reports zolpidem tartrate, the generic form of Ambien, has become the most prescribed drug in the sleep disorder

Verispan’s Vector One®: Generic Ambien Becomes No. 1 Sleep ...  -  May 22, 2007
Business Wire (press release),According to VONA, predictably most switching to zolpidem tartrate came from prior users of its branded equivalent and prior market leader, Ambien (87%).

Wockhardt launches insomnia drug Zolpidem in US  -  May 21, 2007
Moneycontrol.com,Zolpidem tartrate is one of the most widely used medicines to treat insomnia (sleep disorder) and is safer than most other sleeping pills in replicating

Actavis Launches Zolpidem Tablets in the US  -  Apr 27, 2007
PR-Inside.com (Pressemitteilung),Annual sales of Zolpidem Tartrate tablets in the US were approximately $2.2 billion for the twelve months ending December 2006 according to IMS Health data.

Ranbaxy gets US FDA nod for Zolpidem Tablets  -  Apr 26, 2007
Myiris.com,Zolpidem Tartrate Tablets are prescribed for the short-term treatment of insomnia, characterized by difficulty with sleep intervention.

FDA Approves First Generic Versions of Ambien for Insomnia  -  Apr 25, 2007
MedIndia,The US Food and Drug Administration (FDA) today approved the first generic versions of Ambien (zolpidem tartrate) immediate-release tablets.

Ranbaxy says gets US nod for zolpidem  -  Apr 26, 2007
Reuters India,...said on Thursday it had approval from the US Food and Drug Administration to manufacture and market zolpidem tartrate tablets, used to treat insomnia.

FDA OKs two Ranbaxy generics  -  Apr 27, 2007
Bizjournals.com,Ranbaxy will begin making Zolpidem Tartrate tablets, the generic equivalent to Sanofi Aventis US LLC's Ambien, for use in the treatment of insomnia.

Ranbaxy gets US nod for insomnia drug  -  Apr 26, 2007
Andhra Cafe,Ranbaxy Laboratories Ltd said that it had approval from the US Food and Drug Administration to manufacture and market Zolpidem Tartrate tablets,

Aurobindo gets USFDA nod for Zolpidem  -  May 7, 2007
Financial Express,Recently, Ranbaxy Laboratories and Dr Reddys Laboratories (DRL) had also received USFDA approval to manufacture and market Zolpidem Tartrate tablets in the

Business day: Bank sale blocked  -  May 4, 2007
Napa Valley Register,A patent held by Paris-based Sanofi-Aventis on the drug, also called zolpidem tartrate, expired Saturday. The approvals of generic versions of the drug come

Dr. Reddy's Announces the Launch of Zolpidem Tartrate Tablets  -  26 Apr 2007
PipelineReview.com (press release),Zolpidem Tartrate Tablets are the generic version of Sanofi-Aventis' Ambien® Tablets. Ambien Tablets had US sales of approximately $2.1 billion for the same

3 Indian firms get FDA nod for sleep disorder drug  -  26 Apr 2007
Business Standard,Zolpidem tartrate tablets are indicated for the short-term treatment of insomnia and related disorders and the drug had sales of about $ 659 million in the

FDA OKs two Ranbaxy generics  -  26 Apr 2007
Jacksonville Business Journal,Ranbaxy will begin making Zolpidem Tartrate tablets, the generic equivalent to Sanofi Aventis US LLC's Ambien, for use in the treatment of insomnia.

Roxane Laboratories, Inc. Announces Launch of Zolpidem Tartrate ...  -  Apr 23, 2007
PR-Inside.com (Pressemitteilung),Roxane Laboratories' Zolpidem Tartrate Tablets CIV, 5 mg and 10mg are AB rated to AMBIEN(R) (zolpidem tartrate) Tablets CIV, 5 mg and 10mg.

Mylan Announces Final FDA Approval and Immediate Shipment of ...  -  Apr 23, 2007
PR-Inside.com (Pressemitteilung),Zolpidem Tartrate Tablets are the generic version of Sanofi-Aventis' Ambien(R) Tablets. Ambien Tablets had US sales of approximately $2.2 billion for the

Health and Science News Roundup  -  Apr 24, 2007
Monsters and Critics.com,The immediate-release tablets of Zolpidem tartrate provide a sedative-hypnotic drug indicated for the short-term treatment of the medical condition.

Ranbaxy Receives Tentative FDA Approval to Manufacture and Market ...  -  Mar 28, 2007
Drug Newswire (press release),..."We are pleased to receive this tentative approval for Zolpidem Tartrate Tablets. This product will be launched following final approval from the FDA and

Barr challenges Sanofi's Ambien CR insomnia drug  -  Apr 9, 2007
SpiritIndia,Ambien CR (Zolpidem Tartrate Extended-Release Tablets) 6.25mg & 12.5mg is indicated for the treatment of insomnia, characterized by difficulties with sleep

Market Report -- In Play (BRL)  -  Apr 9, 2007
MSN MoneyBarr Laboratories, has initiated a patent challenge for Sanofi-Aventis's (SNY) Ambien CR (Zolpidem Tartrate Extended-Release Tablets), 6.25mg & 12.5mg.

Barr Confirms Patent Challenge of Ambien CR(R)  -  Apr 6, 2007
PR Newswire (press release),This action formally initiates the patent challenge process under the Hatch-Waxman Act. Ambien CR (Zolpidem Tartrate Extended-Release Tablets) 6.25mg

:
 
Web health.mongabay.com


Health Home | Conditions | Cancer | Medications | Surgery | Vaccines

mongabay.com


Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com lead to other sites. health.mongabay.com does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com responsible for dead or misdirected links.


COPYRIGHT 2007 MONGABAY.COM